Tuesday, August 30, 2011 7:50:50 AM
The Board of Directors of Stereotaxis, Inc. (NASDAQ: STXS) announced today following its regularly scheduled board meeting that it reaffirmed the Company's plans for both the launch of the Epoch™ platform and expansion of the Odyssey™ platform into standard labs.
"At our meeting last week, the Board reviewed and endorsed the commercial strategies put forth for the launch of Epoch, as well as for the expansion of Odyssey's market penetration into standard labs," said Fred A. Middleton, Chairman of the Board of Directors. "We are encouraged by the positive early physician feedback to Epoch's productivity enhancements, and remain optimistic about the commercial potential for the Epoch magnetic surgery platform for robotic assisted surgeries in the cardiology suite. We are also encouraged by the positive trends in recurring revenue as reflected in our financial statements."
Mr. Middleton added, "The Board has established a Strategy Committee to evaluate various capital raising strategies to fund the Company's planned growth initiatives over the next 18 months, and we are focused on non-equity sources of funding as our first choice for raising capital since we believe our common stock is significantly undervalued in the public market."
The Company also completed last week its previously announced plans for operating expense reductions amounting to approximately 15 to 20% of annual operating expenses.
About Stereotaxis www.stereotaxis.com www.odysseyexperience.com
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.
Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.
The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
SOURCE Stereotaxis, Inc.
LET'S ALL MAKE SOME $$$$$$$
Recent STXS News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 08:21:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:06:02 PM
- Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States • GlobeNewswire Inc. • 03/04/2024 09:06:00 PM
- Stereotaxis Reports 2023 Full Year Financial Results • GlobeNewswire Inc. • 03/04/2024 09:05:00 PM
- Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology • GlobeNewswire Inc. • 02/22/2024 09:15:00 PM
- Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 • GlobeNewswire Inc. • 02/20/2024 02:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:26:22 PM
- Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter • GlobeNewswire Inc. • 01/08/2024 01:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:00:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:00:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:00:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:00:19 PM
- Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients • GlobeNewswire Inc. • 11/28/2023 01:42:00 PM
- Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 01:54:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 02:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:05:40 PM
- Stereotaxis Reports 2023 Third Quarter Financial Results • GlobeNewswire Inc. • 11/09/2023 02:00:00 PM
- Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States • GlobeNewswire Inc. • 10/31/2023 12:57:00 PM
- Stereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023 • GlobeNewswire Inc. • 10/17/2023 01:05:00 PM
- Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation • GlobeNewswire Inc. • 10/04/2023 12:49:00 PM
- Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology • GlobeNewswire Inc. • 09/06/2023 12:56:00 PM
- Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment • GlobeNewswire Inc. • 08/30/2023 12:49:00 PM
- Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium • GlobeNewswire Inc. • 08/16/2023 12:40:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 01:05:53 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM